PTIX (Protagenic Therapeutics) Insider Ownership: 70.04 % (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics Insider Ownership?

Protagenic Therapeutics PTIX +8.02% 22 Insider Ownership is 70.04 % as of Aug. 01, 2026. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Protagenic Therapeutics's insider ownership is 70.04%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Protagenic Therapeutics's Institutional Ownership is 3.69%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Protagenic Therapeutics's Float Percentage Of Total Shares Outstanding is 96.32%.

Protagenic Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics Insider Ownership Chart

Protagenic Therapeutics Historical Data

The historical data trend for Protagenic Therapeutics can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Insider Ownership 70.04 70.04 70.04 70.04 70.04 70.04 70.04 70.04 70.04 70.04
PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 70.04 % mean?
Protagenic Therapeutics (PTIX) has a Insider Ownership of 70.04 % as of Aug. 01, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Protagenic Therapeutics and its competitors.
Is Protagenic Therapeutics' Insider Ownership too high?
Protagenic Therapeutics' current Insider Ownership is 70.04 %. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Insider Ownership compare to CERO and CYTOF?
Protagenic Therapeutics' Insider Ownership of 70.04 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current Insider Ownership is 70.04 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Insider Ownership of 70.04 %. The current Insider Ownership is 70.04 %. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Insider Ownership is 70.04 % as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price